Sermorelin Super-Responder Profile: Who Gets the Best Results and Why

Does sermorelin have a proven super-responder profile?

No. Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone, the shortest synthetic peptide with the full biological activity of GHRH, and it makes the pituitary release the body's own growth hormone rather than supplying growth hormone itself [6]. The closest thing to response data is one large pediatric growth trial and one small hormone study in older men, both described below.

What the largest trial showed

The Geref International Study Group trial (Thorner et al., 1996) was an open-label, multicenter, 1-year study of 110 previously untreated prepubertal children with growth hormone deficiency, 86 evaluable, given 30 micrograms/kg subcutaneously at bedtime [1]. Mean height velocity rose from 4.1 cm/yr to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months, and 74% were good responders at 6 months [1]. Fasting glucose did not change, IGF-I was not excessively raised, and the treatment was well tolerated overall [1].

The older-men study

A 1992 study enrolled 10 healthy older men (mean age 68) and 9 younger men (mean age 26) [2]. The older men received 0.5 mg and 1 mg in random order, each twice daily for 14 days, with a 14-day period without treatment between doses [2]. At baseline, the older men had lower IGF-I and a shorter mean peak duration of spontaneous GH release than the young men [2]. At 1 mg twice daily, 24-hour GH, area under peaks, peak amplitude and IGF-I all rose significantly versus the older men's baseline, and none differed significantly from the young men afterward [2]. This was a short physiology study, not a clinical-benefit trial [2].

Dose

No sermorelin product is FDA-approved today, so there is no current approved dose [3]. The doses used in the studies above were 30 micrograms/kg nightly in children [1] and 0.5 mg or 1 mg twice daily for 14 days in older men [2]. These are study doses, not recommended doses.

Regulatory status and sport

Geref was approved in 1990 as a diagnostic test of pituitary GH reserve and in 1997 for pediatric GH deficiency [3]. The manufacturer discontinued it in 2008 and FDA withdrew both approvals effective June 18, 2009, later determining it had not been withdrawn for safety or effectiveness [3]. It was never approved for adults, anti-aging, weight loss or athletic performance [3]. Sermorelin sold today is compounded, and compounded drugs are not FDA-approved [8]. HealthRX.com offers sermorelin by prescription. WADA's 2026 Prohibited List names sermorelin in S2.2.4, prohibited at all times [5], and so does the 2027 List [9].